PYC Therapeutics Limited (ASX:PYC)
Australia · Delayed Price · Currency is AUD | Market Cap | 1.30B +80.2% |
| Revenue (ttm) | 20.56M -17.7% |
| Net Income | -47.56M |
| EPS | -0.09 |
| Shares Out | 983.51M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,528,300 |
| Average Volume | 1,730,137 |
| Open | 1.400 |
| Previous Close | 1.430 |
| Day's Range | 1.320 - 1.415 |
| 52-Week Range | 0.847 - 1.755 |
| Beta | 1.05 |
| RSI | 66.43 |
| Earnings Date | May 22, 2026 |
About PYC Therapeutics
PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of drug solutions in the areas of ribonucleic acid therapeutics in Australia. The company's preclinical development programs include VP-001, drug program for retinitis pigmentosa type 11; and PYC-001, a drug program for the treatment of autosomal dominant optic atrophy. It also focuses on the development of programs for kidney, retinal, and central nervous system diseases. PYC Therapeutics Limited has academic-industry collaborations with Murdoch Univ... [Read more]
Financial Performance
In fiscal year 2025, PYC Therapeutics's revenue was 23.49 million, an increase of 6.51% compared to the previous year's 22.06 million. Losses were -50.30 million, 33.3% more than in 2024.
Financial StatementsNews
PYC Therapeutics Earnings Call Transcript: Q1 2026
Recent financing has secured over $750 million in cash runway, enabling advancement of four decorrelated pipeline assets through key clinical milestones. Regulatory and clinical variability may affect timelines, but strong investor alignment and strategic focus support long-term growth.
PYC Therapeutics Transcript: AGM 2025
The meeting featured board renewal, strong support for resolutions, and a strategic focus on advancing four rare disease drug programs, with key clinical milestones and commercial opportunities expected over the next 24 months. Funding is secured through 2028, and leadership is committed to long-term growth.
PYC Therapeutics Transcript: Investor Update
Board and management changes address past strategic misalignments, with a renewed focus on advancing all four clinical programs and strengthening commercial capabilities. Key milestones across the pipeline are expected over the next 24 months, aiming to close the gap between intrinsic value and market capitalization.
PYC Therapeutics Earnings Call Transcript: Q3 2025
Pipeline assets targeting PKD, PMS, and ophthalmology indications are set for major efficacy data readouts within 12–24 months, with large market opportunities and strong preclinical support. Near-term milestones and positive regulatory engagement position the company for significant value creation.
PYC Therapeutics Earnings Call Transcript: Q2 2025
Four clinical-stage assets are advancing, with key efficacy data and regulatory milestones expected by year-end. Strong industry interest and sufficient capital support continued development, with out-licensing options available to fund the pipeline.
PYC Therapeutics Earnings Call Transcript: Q1 2025
Three clinical-stage programs are advancing rapidly, with major data readouts and regulatory milestones expected in 2025. Strong cash reserves support a 24-month runway, and the company is positioned for significant value creation through clinical efficacy, business development, and potential licensing deals.
PYC Therapeutics Transcript: AGM 2024
The meeting highlighted strong clinical progress across a broad pipeline, increased share price, and strategic plans to transition to a commercial-stage company. Key resolutions, including share consolidation and director re-election, received strong support. Capital access and organizational scaling remain top priorities.
PYC Therapeutics Earnings Call Transcript: Q3 2024
Multiple first-in-class RNA therapies are advancing through clinical development, with early RP11 data showing both safety and functional vision improvement. Key regulatory milestones and pivotal trial planning are underway, positioning the pipeline for significant value inflection in the next 12–18 months.